A collaborative study on the malignant syndrome in Parkinson's disease and related disorders

Delay, 1968, Drug-induced extrapyramydal syndromes, vol. 2, 248 Meltzer, 1973, Rigidity, hyperpyrexia and coma following fluphenazine enanthate, Psychopharmacologia (Berl.), 29, 337, 10.1007/BF00429281 Caroff, 1980, The neuroleptic malignant syndrome, J Clin Psychiatry, 41, 79 Levenson, 1985, Neuroleptic malignant syndrome, Am J Psychiatry, 142, 1137, 10.1176/ajp.142.10.1137 Addonizio, 1987, Neuroleptic malignant syndrome. Review and analysis of 115 cases, Biol Psychiatry, 22, 1004, 10.1016/0006-3223(87)90010-2 Henderson, 1981, Neuroleptic malignant syndrome. A pathogenetic role for dopamine receptor blokade?, Neurology, 31, 132, 10.1212/WNL.31.2.132 Toru, 1981, Neuroleptic malignant syndrome-like state following a withdrawal of anti-parkinsonian drugs, J Nerv Ment Dis, 169, 324, 10.1097/00005053-198105000-00011 Fujitake, 1984, Neuroleptic malignant syndrome-like state in eight patients with parkinsonism, Rinshoshinkeigaku, 24, 371 Sechi, 1984, Fatal hyperpyrexia after withdrawal of levodopa, Neurology, 34, 249, 10.1212/WNL.34.2.249 Figa-Talamanca, 1985, Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause, Neurology, 35, 258, 10.1212/WNL.35.2.258 Kuno, 1990, Neuroleptic malignant syndrome associated with withdrawal of anti-parkinsonian drugs, vol. 2, 245 Keyser, 1991, Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy, Arch Intern Med, 151, 794, 10.1001/archinte.151.4.794 Simpson, 1984, Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine, Am J Psychiatry, 141, 796, 10.1176/ajp.141.6.796 Pfeiffer, 1989, On-off-induced lethal hyperthermia, Mov Disord, 4, 338, 10.1002/mds.870040408 Mezaki, 1989, Benign type of malignant syndrome, Lancet, 1, 49, 10.1016/S0140-6736(89)91710-8 Kuno, 1997, Neuroleptic malignant syndrome in parkinsonian patients; Risk factors, Eur Neurol, 38, 56, 10.1159/000113484 Gibb, 1988, Neuroleptic malignant syndrome in striatonigral degeneration, Br J Psychiatry, 153, 254, 10.1192/bjp.153.2.254 Konagaya, 1997, Malignant syndrome in multiple system atrophy, No to Shinkei, 49, 516 Ueda, 1996, Monoamine imbalance of the central nervous system in a case of Shy-Drager syndrome with recurrent attacks of a neuroleptic malignant syndrome, Rinshoshinkeigaku, 36, 696 Ohta, 1974, New grading of level of disordered consciousness, Shinkeigekagaku, 2, 623 Gronert, 1988, Aetiology of malignant hyperthermia, Br J Anesth, 60, 253, 10.1093/bja/60.3.253 Mickelson, 1988, Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia, J Biol Chem, 263, 9310, 10.1016/S0021-9258(19)76541-7 MacLennan, 1990, Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia, Nature, 343, 559, 10.1038/343559a0 McCarthy, 1990, Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2, Nature, 343, 562, 10.1038/343562a0 Quane, 1994, Detection of a novel common mutation in the ryanodine receptor gene in the malignant hyperthermia: implications for diagnosis and heterogeneity studies, Hum Mol Genet, 3, 471, 10.1093/hmg/3.3.471 Miyatake, 1996, No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated malignant hyperthermia, J Neurol Sci, 143, 161, 10.1016/S0022-510X(96)00015-9 Horn, 1988, Hypothalamic pathology in the neuroleptic malignant syndrome, Am J Psychiatry, 145, 617, 10.1176/ajp.145.5.617 Cox, 1977, Do central dopamine receptors have a physiologic role in thermoregulation?, Br J Pharmacol, 61, 83, 10.1111/j.1476-5381.1977.tb09742.x Parada, 1995, Sulpiride increases and dopamine decreases intracranial temperature in rat when injected in the lateral hypothalamus: an animal model for the neuroleptic malignant syndrome?, Brain Res, 674, 117, 10.1016/0006-8993(94)01455-Q Chen, 2000, Regulatory effects of D2 receptors in the ventral tegmental area on the mesocorticolimbic dopaminergic pathway, J Neurochem, 74, 2576, 10.1046/j.1471-4159.2000.0742576.x Jones, 1989, Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology, J Neurol Neurosurg Psychiatry, 52, 1006, 10.1136/jnnp.52.8.1006 Martin, 1988, Muscle pathology in the neuroleptic malignant syndrome, Am J Psychiatry, 145, 617, 10.1176/ajp.145.5.617 Yamawaki, 1991, Successful treatment of levodopa-induced neuroleptic malignant syndrome with disseminated intravascular coagulation in a patients with Parkinson's disease, Rinshoshinnkeigaku, 31, 62 Mueller, 1983, Neuroleptic malignant syndrome. Successful treatment with bromocriptine, JAMA, 249, 386, 10.1001/jama.249.3.386 Pearlman, 1986, Neuroleptic malignant syndrome: A review of literature, J Clin Psychopharmacol, 6, 257, 10.1097/00004714-198610000-00002